TREATMENT OF KAPOSI'S SARCOMA WITH ICRF-159 (NSC-129943)OLWENY CLM; MASABA JP; SIKYEWUNDA W et al.1976; CANCER TREATM. REP.; U.S.A.; DA. 1976; VOL. 60; NO 1; PP. 111-113; BIBL. 7 REF.Article

UTILIZATION OF AN ENANTIOMER AS A SOLUTION TO A PHARMACEUTICAL PROBLEM: APPLICATION TO SOLUBILIZATION OF 1,2-DI(4-PIPERAZINE-2,6-DIONE) PROPANEREPTA AJ; BALTEZOR MJ; BANSAL PC et al.1976; J. PHARM. SCI.; U.S.A.; DA. 1976; VOL. 65; NO 2; PP. 238-242; BIBL. 30 REF.Article

CLINICAL TRIALS WITH BIS-DIOXOPIPERAZINE PROPANE (ICRF 159; NSC 129, 943) IN ACUTE LEUKAEMIAS.KREPLER P; PAWLOWSKY J.1975; OESTERR. Z. ONKOL.; OESTERR.; DA. 1975; VOL. 2; NO 4; PP. 112-114; ABS. ALLEM.; BIBL. 3 REF.Article

RAZOXANE: A NEW ANTI-TUMOUR AGENT.1978; DRUG THERAPEUT. BULL.; G.B.; DA. 1978; VOL. 16; NO 2; PP. 7-8; BIBL. 17 REF.Article

Stereoselective hydrolysis of ICRF-187 (dexrazoxane) and ICRF-186 by dihydropyrimidine amidohydrolaseHASINOFF, B. B.Chirality (New-York, NY). 1994, Vol 6, Num 3, pp 213-215, issn 0899-0042Article

Strategies for prevention of anthracycline cardiotoxicityBASSER, R. L; GREEN, M. D.Cancer treatment reviews. 1993, Vol 19, Num 1, pp 57-77, issn 0305-7372Article

DER EINFLUBETA DER BIS-DIOXOPIPERAZINE ICRF 159 UND ICRF 154 AUF DIE CADMIUM-AUSSCHEIDUNG IM URIN BEI CADMIUM-VERGIFTETEN RATTEN = EFFET DES BIS-DIOXOPIPERAZINES ICRF 159 ET ICRF 154 SUR L'EXCRETION URINAIRE DU CADMIUM CHEZ LES RATS INTOXIQUES AU CADMIUMWITTING U; BERTRAM HP; SCHUMACHER E et al.1979; INTERNATION. ARCH. OCCUP. ENVIRONMENT. HEALTH; DEU; DA. 1979; VOL. 42; NO 3-4; PP. 365-373; ABS. ENG; BIBL. 11 REF.Article

STUDIES ON THE STABILITY AND CELLULAR DISTRIBUTION OF DIOXOPIPERAZINES IN CULTURED BHK-21 S CELLS.DAWSON KM.1975; BIOCHEM. PHARMACOL.; G.B.; DA. 1975; VOL. 24; NO 24; PP. 2249-2253; BIBL. 24 REF.Article

Reduction of chronic doxorubicin cardiotoxicity in beagle dogs by bis-morpholinomethyl derivative of razoxane (ICRF-159)HERMAN, E. H; FERRANS, V. J; BHASKER BHAT, H et al.Cancer chemotherapy and pharmacology. 1987, Vol 19, Num 4, pp 277-281, issn 0344-5704Article

ICRF-159: CURRENT STATUS AND CLINICAL PROSPECTS.BELLET RE; ROSENCWEIG M; VON HOFF DD et al.1977; EUROP. J. CANCER; G.B.; DA. 1977; VOL. 13; NO 11; PP. 1293-1298; BIBL. 36 REF.Article

DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiaeISHIDA, R; HAMATAKE, E; WASSERMAN, R. A et al.Cancer research (Baltimore). 1995, Vol 55, Num 11, pp 2299-2303, issn 0008-5472Article

Radiotherapeutic enhancement by razoxaneHELLMANN, K; RHOMBERG, W.Cancer treatment reviews. 1991, Vol 18, Num 4, pp 225-240, issn 0305-7372Article

Cell cycle progression and chromosome segregation in mammalian cells cultured in the presence on the topoisomerase II inhibitors ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane ; ADR-529] and ICRF-159 (razoxane)GORBSKY, G. J.Cancer research (Baltimore). 1994, Vol 54, Num 4, pp 1042-1048, issn 0008-5472Article

Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivativesTANABE, K; IKEGAMI, Y; ISHIDA, R et al.Cancer research (Baltimore). 1991, Vol 51, Num 18, pp 4903-4908, issn 0008-5472Conference Paper

Response to ICRF-159 in cell lines resistant to cleavable complex-forming topoisomerase II inhibitorsDAVIES, S. L; BERGH, S. J; HARRIS, A. L et al.British journal of cancer. 1997, Vol 75, Num 6, pp 816-821, issn 0007-0920Article